Document:

Modification No. P00005 to Contract Number W9113M-10-0056

 Exhibit 10.3 

 

																													
	AMENDMENT OF SOLICITATION/MODIFICATION OF
CONTRACT	  	1. CONTRACT ID CODE
 V
	  	PAGE OF PAGES
	  	  	1	  	3
	 2. AMENDMENT/MODIFICATION NO.
  
 P00005
	 	
3. EFFECTIVE DATE
  

08/15/2011
	  	 4.
REQUISITION/PURCHASE REQ. NO.
  
 see schedule
	 	5. PROJECT NO. (If applicable)
	 6. ISSUED BY         CODE
	 	W911QY	  	7. ADMINISTERED BY (If other than Item 6) CODE	  	S4801A
	  
 NATICK CONTRACTING DIVISION
 64 Thomas Johnson
Drive
 Frederick MD 21702-4300
	  	  

DCMA
 DCMA-SEATTLE

CORPORATE CAMPUS EAST III
 3009 112TH AVE. NE
STE200
 BELLEVUE WA 98004-8019

																													
	 8. NAME AND ADDRESS
OF CONTRACTOR (No., street, county, State and ZIP Code)
  
 AVI BIOPHARMA INC
 4575 SW RESEARCH WAY STE 200

CORVALLIS OR 97333-1299
	  	(X)	  	9A. AMENDMENT OF SOLICIATION NO.
	  	  
  ̈
	  	
	  	  	 9B. DATED (SEE ITEM 11)

 

	  	x	  	 10A. MODIFICATION OF CONTRACT/ORDER NO.

 
 W9113M-10-C-0056

	  	 	  	 10B. Dated (SEE ITEM 13)

 
 Jul 14, 2010

	 CODE 49WU1
	  	 FACILITY CODE
	  	 	  	 	  	 	  	 	  	 	  

																													
	11.THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	 ̈ The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of
Offers	  	 ̈ is extended,	  	 ̈ is not extended.
	  
 Offers must
acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:
  

(a) By completing items 8 and 15, and returning             copies of the amendment;
(b) By acknowledging receipt of this amendment on each copy of the offer submitted;
  
 or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF
OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment your desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes
reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
  

	 12. ACCOUNTING AND APPROPIRATION DATA
                (If required)
  

See SCHEDULE

																													
	 13. THIS ITEM ONLY APPLIES TO MODIFICATION OF
CONTRACTS/ORDERS.
 IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	 CHECK ONE
	  	A. THIS CHANGE ORDER IS ISSUED PURSUANT TO:     (Specify authority)
            THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
	
 ̈
	  
	
 ̈
	  	B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES     (such as
changes in paying office, appropriation date, etc. ) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
	
x
	  	 C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PRUSUANT TO AUTHORITY
OF:
  
 Mutual Agreement of Both Parties

	
x
	  	D. OTHER    (Specify type of modification and
authority)

																													
	 E. IMPORTANT:
	  	Contractor      ̈ is
not,         x is required to sign this document and return
            1             copies to the issuing office.
	 14. DESCRIPTION OF AMENDMENT/MODIFICATION ( Organized by UCF section headings,
including solicitation/contract subject matter where feasible.)
  
 See
Attached Summary of Changes.
  
 Except as provided herein, all terms and
conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

																													
	 15A. NAME AND TITLE OF SIGNER (Type or print)

Chris Garabedian
 President and
CEO
	  	 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

Sandra J. O’Connell
  
 Contracting Officer

	 15B. CONTRACTOR/OPERATOR

 
 /s/ Chris
Garabedian                            

(Signature of person authorized to sign)
	  	 15C. DATE SIGNED

 
 9/23/11
	  	 16B. UNITED STATES OF AMERICA

 
 /s/ Sandra J.
O’Connell                        
 (Signature of Contracting Officer)
	  	 16C. DATE SIGNED

 
 9/26/11

	 NSN 7540-01-152-8070

Previous edition unusable
	  	 STANDARD FORM 30 (Rev. 10-83)

Prescribed by GSA FAR (48 CFR) 53.243

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  
 W9113M-10-C0056

 (soconnell 13438) 
 Page 2 of 3 

 SECTION SF 30 BLOCK 14 CONTINUATION PAGE 
 SUMMARY OF CHANGES 
  

	 	A.	The purpose of this modification is to move studies/tasks originally planned in Option CLINs 0002 and 0006 into CLINs 0001 and 0005 thereby affecting the total cost and
schedule of this contract as shown below. 

  

	 	1.	SECTION A—SOLICITATION/CONTRACT FORM 

 The total cost of this contract was increased by $46,142,707.00 from $80,396,827.37 to $126,539,534.37. 
  

	 	2.	SECTION B—SUPPLIES OR SERVICES AND PRICES 

 CLIN 0001 
 The target cost has increased by $[†] from $[†] to $[†].

 The target profit/fee has increased by $[†] from $[†] to $[†]. 

The minimum profit fee has increased by $[†] from $[†] to $[†]. 

The maximum profit fee has increased by $[†] from $[†] to $[†]. 

The total cost of this line item has increased by $[†] from $[†] to $[†]. 

CLIN 0002 
 The
target cost has decreased by $[†] from $[†] to $[†]. 
 The target profit/fee has decreased by $[†] from
$[†] to $[†]. 
 The minimum profit fee has decreased by $[†] from $[†] to $[†]. 

The maximum profit fee has decreased by $[†] from $[†] to $[†]. 

The total cost of this line item has decreased by $[†] from $[†] to $[†]. 

CLIN 0005 
 The
target cost has increased by $[†] from $[†] to $[†]. 
 The target profit/fee has increased by $[†] from
$[†] to $[†]. 
 The minimum profit fee has increased by $[†] from $[†] to $[†]. 

The maximum profit fee has increased by $[†] from $[†] to $[†]. 

The total cost of this line item has increased by $[†] from $[†] to $[†]. 

CLIN 0006 
 The
target cost has decreased by $[†] from $[†] to $[†]. 
 The target profit/fee has decreased by $[†] from
$[†] to $[†]. 
 The minimum profit fee has decreased by $[†] from $[†] to $[†]. 

The maximum profit fee has decreased by $[†] from $[†] to $[†]. 

The total cost of this line item has decreased by $[†] from $[†] to $[†]. 

 

	 	3.	SECTION F - DELIVERIES OR PERFORMANCE 

 The following Delivery Schedule item for CLIN 0001 has been changed from: 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  
 W9113M-10-C0056

 (soconnell 13438) 
 Page 3 of 3 

											
	 DELIVERY DATE
	  	 	QUANTITY	  	  	SHIP TO ADDRESS	  	 	UIC	  
	  

25-MAR-2012
	  				  	  
 N/A
 FOB: Destination
	  			

 To: 
  

							
	DELIVERY DATE	  	QUANTITY	  	SHIP TO ADDRESS	  	UIC
	18-APR-2013	  		  	N/A FOB: Destination	  	

 The following Delivery Schedule item for CLIN 0005 has been changed from: 

 

							
	DELIVERY DATE	  	QUANTITY	  	SHIP TO ADDRESS	  	UIC
	01-APR-2012	  		  	N/A FOB: Destination	  	

 To: 
  

							
	DELIVERY DATE	  	QUANTITY	  	SHIP TO ADDRESS	  	UIC
	10-MAY-2013	  		  	N/A FOB: Destination	  	

 4. SECTION J — LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS 

Attachment No. 1 Contractor’s Statement of Work — Ebola Virus, Dated 3/11/10 and Attachment No. 2 Contractor’s
Statement of Work — Marburg Virus, Dated 3/11/10 are replaced in their entirety with the Attachments to this modification. 
  

	 	B.	An Integrated Baseline Review (IBR) will be held within 3 months of the date of this modification. At that time the Performance Measurement Baseline (PMB) will be
approved by the Government for the changed efforts of CLINs 0001; 0002, 0005 and 0006. A modification will be executed upon acceptance of the PMB, and will incorporate any approved changes to the budget that are required. 

 

	 	C.	As a result of this modification all other terms and conditions of this contract are unchanged and remain in full force and effect. 

(End of Summary of Changes) 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Appendix B: Revised Statement of Work 

3.0 CONTRACT 
 AVI BioPharma (AVI)
Statement of Work for AVI-6002 as an effective therapeutic for ebolavirus: 
 3.2 CLIN0001 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.2.2
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.2.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	1
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.2.2.1.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 

3.2.2.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.2.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.2.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.2.2.2 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	2
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.2.3 [†]: [†] 

[†] 
 Period
of Work: [†]. 
 Deliverable: [†]. 
 3.2.3.1 [†]: [†]. 
 Period of Work: [†]. 

Deliverable: [†]. 

3.2.3.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.3.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.3.1.3 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	3
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 [†] 
 Period of Work: [†]. 
 Deliverable: [†] 

3.2.3.1.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.3.2.1 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.2.3.2.2 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	4
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†] 
 3.2.3.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.2.3.2.4 [†]: [†] 

Period of Work: [†] 

Deliverable: [†] 
 3.2.4
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 
 3.2.4.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.1.1 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	5
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.2.4.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.1.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.1.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.2 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	6
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.2.4.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.2.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.2.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	7
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.2.4.3 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.2.4.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.3.2 [†]: [†] 

Period of Work: [†] 

Deliverable: [†] 

3.2.4.3.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.3.4 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	8
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†] 
 3.2.4.3.5 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 
 3.2.5
[†]: [†] 
 Period of Work: [†] 
 Deliverable: [†] 
 3.2.5.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	9
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.2.5.3 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.2.5.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.5.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.5.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.5.7 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.5.8 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	10
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†] 
 3.2.5.9 [†]: [†]. 
 Period of Work: [†]. 

Deliverable: [†]. 
 3.2.6
[†]: [†] 
 [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.2.6.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.6.2 [†]: [†] 

Period of Work: [†]. 

Deliverable:. [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	11
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.2.6.3 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.2.7 [†]: [†] 

[†] 
 Period
of Work: [†]. 
 Deliverable: [†]. 
 3.2.7.1 [†]: [†]. 
 Period of Work: [†]. 

Deliverable: [†]. 

3.2.7.2 Finance and EVMS: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.7.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.2.7.4 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	12
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3 [†]: [†] 

[†] 
 Period
of Work: [†]. 
 Deliverable: [†]. 
 3.3.1 [†]:[†] 
 [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.1.1 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	13
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†] 
 3.3.1.2 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 
 3.3.2
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 
 3.3.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

[†] 
 3.3.2.1.1 [†]:
[†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	14
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.3.2.1.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.3.2.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.1.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	15
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.3.2.2.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.3.2.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.3 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	16
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	 AVI BioPharma, Inc.
	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.2.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	17
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.3.2.6 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.3.3 [†]: [†] 
 Period
of Work: [†]. 
 Deliverable: [†]. 
 3.3.3.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†] 

3.3.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.3.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	18
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.3.4. [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.3.4.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.4.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.4.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.4.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.4.5 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	19
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.4.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.3.5
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 
 3.3.5.1 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	20
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†] 
 3.3.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.5.3 [†]: [†] 

Period of Work: [†] 

Deliverable: [†] 
 3.3.6
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	21
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.3.6.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 

3.3.6.2 [†]: [†] 

Periods of Work: [†] 

Deliverable: [†] 

3.3.6.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.3.7
[†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	22
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.7.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.7.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 CLIN0001
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.8. [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.8.1 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	23
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.8.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.8.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.8.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.8.5 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
	`	  	Use or disclosure of data contained on this sheet is subject to the	  	24
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.9 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.9.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.9.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.9.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.9.4 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	25
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.9.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.10 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.10.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.10.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.11 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	26
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.3.11.1 [†]: [†] 
 Period of Work: [†] 
 Deliverable: [†]. 

3.3.11.2 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.3.11.3 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.3.11.4: [†]. [†] 

Period of Work: [†] 

Deliverable: [†] 

3.3.11.5 [†]. [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.3.11.6 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	27
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.11.7 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.11.8 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.11.9 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.11.10 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.3.12 [†]. [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	28
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.12.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.12.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.12.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	29
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.3.12.4 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.3.13 [†]: [†] 
 Period
of Work: [†]. 
 Deliverable: [†] 
 3.3.13.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.3.13.2 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	30
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.3.13.3 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.3.13.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.13.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.14. [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.14.1 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	31
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.3.14.2 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.3.14.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.3.15
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.15.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.15.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.15.3 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	32
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.16.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	33
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.3.16.2.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.3.16.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.17.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.17.1.1 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	34
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†] 
 3.3.17.1.2 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†] 

3.3.17.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.17.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.17.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.17.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.17.2.4 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	35
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.3.17.2.5 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.3.17.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.4
CLIN0002: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.1: [†]. [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.1.1: [†]. [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	36
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.4.1.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 

3.4.1.3: [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.4.2
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	37
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.4.2.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.4.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.2.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.4.3
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	38
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.4.3.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.4.3.1.1 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.4.3.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.3.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.3.1.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	39
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.4.3.1.5 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.4.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.3.2.1 [†].[†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.3.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.3.2.3 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	40
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.4.3.3 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.4.3.4: [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.4.4
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.4.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.4.2 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	41
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.4.4.3 [†]: [†]. 
 Period of Work: [†]. 

Deliverable: [†]. 

3.4.4.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.4.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.4.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.4.7 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.4.5
[†]: [†] 
 Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	42
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.4.5.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.4.5.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.5.3 [†]: [†] 

Period of Work: [†] 

Deliverable: [†] 

3.4.5.4 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	43
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.6.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.6.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.6.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.6.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	44
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.4.6.2.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.4.6.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.6.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.6.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.4.7
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.7.1 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	45
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.7.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.7.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.7.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.4.8
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.8.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.8.2 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	46
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.4.8.3 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.4.8.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.8.5 [†]: [†]. 
 3.4.8.6
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.8.7 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.8.8 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.8.9 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	47
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.4.9 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.9.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	48
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.4.9.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 

3.4.9.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.4 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	49
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†] 
 3.4.9.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.10 [†]: [†] 
 Period
of Work: [†]. 
 Deliverable: [†]. 
 3.4.10.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.4.10.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.10.3 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	50
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.11 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.11.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.11.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.11.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	51
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.4.11.4 [†]: [†] 
 Period of Work: [†] 
 Deliverable: [†]. 

3.4.12 [†]: [†] 
 Period
of Work: [†]. 
 Deliverable: [†] 
 3.4.12.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†] 

3.4.12.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.13 [†]: [†] 
 3.4.14
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.14.1 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	52
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†] 
 3.4.14.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.1.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.2 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	53
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.4.14.2.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.2.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.2.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.3 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	54
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.14.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.14.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.14.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.15 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	55
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.15.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.15.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.15.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.15.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.5
CLIN0003: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.5.1 [†]: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	56
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.5.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.5.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.5.3
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.5.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.5.3.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.5.3.1.2 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.5.3.1.3 [†]: [†] 

Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	57
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.5.3.1.4 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 
 3.5.3.2 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	58
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 

Deliverable: [†]. 
 3.5.3.2.1 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.5.3.2.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.5.3.2.3 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.5.3.2.4 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.2.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	59
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.5.3.3 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.5.3.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.3.2 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.4 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†] 

3.5.3.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.5.4
[†]: [†] 
 Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	60
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.5.4.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.5.4.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.5.4.3
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.5.4.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.5.5
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.5.5.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.5.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.5.6
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.5.6.1 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	61
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3. 5.6.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.6.3 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.6.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.6
CLIN0004: [†] 
 Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	62
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.6.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.6.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.2 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	63
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.6.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.6.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.6.3
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 
 3.6.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	64
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 3.6.3.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.6.3.3 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.6.3.4 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 

3.6.4 [†]: [†] 
 Period
of Work: [†]. 
 Deliverable: [†]. 
 3.6.4.1 [†]: [†] 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	65
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.6.4.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.6.5
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.6.5.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.6.6
[†]: [†] 
 Period of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	66
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.6.6.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.6.6.2 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.6.6.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.7 [†]: [†] 
 Period
of Work: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	67
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Deliverable: [†]. 
 3.6.7.1 Program Management: [†]. 
 Period of Work: [†]. 

Deliverable: [†]. 

3.6.7.2 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.7.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.7.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.6.8
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.6.8.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.8.2 [†]: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	68
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	 		 	
	HFV-ZEBOV	 	Final Statement of Work	 	
		 	12 August 2011	 	

  

 Period of Work: [†]. 
 Deliverable: [†]. 

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	69
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Appendix B: Revised
Statement of Work 
 3.0 CONTRACT 
 AVI BioPharma (AVI) Statement of Work for AVI-6003 as an effective therapeutic for Marburgvirus: 

3.2 CLIN0005 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.2.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.2.2.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable:
[†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	1
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.2.2.1.1 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†] 
 3.2.2.1.2 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.2.2.1.3 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.2.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.2.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.2.2.2 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	2
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.2.3 [†]: [†] 

        [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.2.3.1 [†]: [†]. 
 Period of Work: [†]. 
 Deliverable: [†].

 3.2.3.1.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.2.3.1.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.2.3.1.3 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	3
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.2.3.1.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.3.2.1 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	4
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†] 
 Deliverable: [†]. 
 3.2.3.2.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†] 
 3.2.3.2.3 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†] 
 3.2.3.2.3.1 [†]: [†] 
 Period of Work: [†]

 Deliverable: [†] 
 3.2.3.2.4 [†]: [†] 
 Period of Work: [†]

 Deliverable: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	5
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.2.4 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†] 
 3.2.4.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.1.4 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	6
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.2.4.1.5 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.4.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.4.2.1 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.4.2.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	7
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.2.4.2.3 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.2.4.2.4 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.2.4.2.5 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.2.4.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.4.3.1 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	8
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable:
[†]. 
 3.2.4.3.2 [†]: [†] 
 Period of Work: [†] 
 Deliverable: [†]

 3.2.4.3.3 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.2.4.3.4 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]

 3.2.4.3.5 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.2.5 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	9
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†] 
 Deliverable: [†] 
 3.2.5.1 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.5.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.5.3 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.5.4 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.5.5 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	10
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.2.5.6 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.5.7 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.5.8 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†] 
 3.2.5.9 [†]: [†]. 
 Period of Work: [†].

 Deliverable: [†]. 
 3.2.6 [†]: [†] 
 3.2.6.3 [†]: [†] 

 

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	11
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 3.2.7 [†]: [†] 
 [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.2.7.1 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 

3.2.7.2 Finance and EVMS: [†]. 
 Period of Work: [†]. 
 Deliverable: [†]. 

 3.2.7.3 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]

 3.2.7.4 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	12
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3 [†]: [†]

 [†] 
 Period of
Work: [†]. 
 Deliverable: [†]. 
 3.3.1 [†]: [†] 
 [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	13
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.1.2 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 [†]

 3.3.2.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.1.2 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	14
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.3.2.1.3 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.1.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2.2 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	15
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.3.2.2.3 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.2.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.2.3 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	16
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 

3.3.2.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.3.2.3.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†].  
 3.3.2.4 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.3.2.5 [†]: [†] 
 Period of Work: [†].

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	17
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†]

 3.3.2.6 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.3.3 [†]: [†] 
 Period of Work: [†]. 
 Deliverable:
[†]. 
 3.3.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.3.3.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†].  

 

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	18
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.4. [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.4.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.4.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.4.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.4.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	19
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.4.5 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.4.6 [†]: 

[†] 
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.3.5 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	20
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.5.1 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†] 
 3.3.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.5.3 [†]: [†] 

Period of Work: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	21
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†]

 3.3.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.6.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.6.2 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	22
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†]

 3.3.6.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.3.7
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.7.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.7.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

CLIN0005 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	23
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.8. [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.8.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.8.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.8.3 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	24
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†].

 3.3.8.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.8.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.3.9
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.9.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	25
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.9.2 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†] 
 3.3.9.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.9.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.9.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.10 [†]: [†] 
 Period
of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	26
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†].

 3.3.10.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.10.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.11 [†]: [†] 
 Period of
Work: [†] 
 Deliverable: [†]. 
 3.3.11.1 [†]: [†] 
 Period of Work: [†] 

Deliverable: [†]. 

3.3.11.2 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.3.11.3 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	27
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.11.4: [†]. [†]

 Period of Work: [†] 
 Deliverable: [†] 
 3.3.11.5 [†]. [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.3.11.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.11.7 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.11.8 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	28
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.3.11.9 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.3.11.10 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.3.12 [†]. [†] 
 Period
of Work: [†]. 
 Deliverable: [†]. 
 3.3.12.1 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	29
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†] 
 3.3.12.2 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.3.12.3 [†]: [†] 
 Period
of Work: [†]. 
 Deliverable: [†]. 
 3.3.12.4 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	30
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.3.13 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†] 

3.3.13.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†].  

3.3.13.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]  

3.3.13.3 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	31
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†]. 

 3.3.13.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.3.13.5
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.14. [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.14.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.14.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	32
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.14.3 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†] 
 3.3.15 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.15.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.15.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.15.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.1 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	33
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†].

 3.3.16.1.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.3.16.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	34
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.16.3 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.16.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.16.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.17.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.17.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.3.17.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	35
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.17.2 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.3.17.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.17.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.17.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.17.2.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.3.17.2.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	36
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.3.17.3 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4 CLIN0006: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.1: [†]. [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.1.1: [†]. [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	37
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.4.1.3: [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.2.2 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	38
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.4.2.3 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†] 
 3.4.2.4 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.3 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†] 
 3.4.3.1 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	39
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.4.3.1.1 [†]: [†] 
 Period of Work: [†]

 Deliverable: [†]. 
 3.4.3.1.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.3.1.3 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.3.1.4 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]
 3.4.3.1.5 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	40
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.4.3.2 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.3.2.1 [†]. [†] 

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.3.2.2 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.3.2.3 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.3.3 [†]: [†]

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	41
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†].
 3.4.3.4: [†]: [†] 
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.4.4 [†]: [†]
 Period of Work: [†]. 

Deliverable: [†]. 

3.4.4.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.4.4.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	42
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.4.4.3 [†]: [†].

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.4.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]
 3.4.4.5
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.4.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.4.7 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.4.5
[†]: [†] 
 Period of Work: [†]. 

 

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	43
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†].

 3.4.5.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.4.5.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.5.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.5.4 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	44
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.4.6 [†]: [†]  
 Period of Work: [†].

 Deliverable: [†] 
 3.4.6.1 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†].  
 3.4.6.1.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.6.1.3 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.6.2 [†]: [†]  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	45
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.6.2.1 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†].  
 3.4.6.2.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.6.3 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†] 
 3.4.6.4 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.7 [†]: [†] 
 Period of Work: [†].

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	46
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable:
[†]. 
 3.4.7.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.4.7.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.4.7.3 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]

 3.4.7.4 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.4.8 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

 3.4.8.1 [†]: [†] 
 Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	47
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable:
[†]. 
 3.4.8.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.4.8.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.8.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.8.5 [†]: [†]. 

3.4.8.6 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.8.7 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.8.8 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	48
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†]

 3.4.8.9 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.4.9 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

 3.4.9.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]

 3.4.9.1.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.4.9.1.2 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	49
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.9.1.3 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.9.2.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.9.3 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	50
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.9.4 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†] 

3.4.9.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.10 [†]: [†] 
 Period
of Work: [†]. 
 Deliverable: [†]. 
 3.4.10.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	51
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.4.10.2 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.10.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.11 [†]: [†] 
 Period
of Work: [†]. 
 Deliverable: [†] 
 3.4.11.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	52
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.4.11.2 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.11.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.11.4 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.4.12 [†]: [†] 
 Period
of Work: [†]. 
 Deliverable: [†] 
 3.4.12.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†] 

3.4.12.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	53
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.4.13 [†]: [†]

 3.4.14 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 

3.4.14.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.4.14.1.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.4.14.1.3 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	54
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†].  
 3.4.14.1.4 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.14.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†].  
 3.4.14.2.1 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
 3.4.14.2.2 [†]: [†] 
 Period of Work: [†].

 Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	55
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.4.14.2.3 [†]:
[†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.14.2.4 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.14.2.5 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.14.3 [†]: [†] 

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.14.3.1 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.14.3.2 [†]: [†]

 Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	56
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†]

 3.4.14.4 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]

 3.4.14.5 [†]: [†]  
 Period of Work: [†]. 
 Deliverable: [†].

 3.4.15 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

 3.4.15.1 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†].

  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	57
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.4.15.2 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†].  
 3.4.15.3 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.4.15.4 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†] 
 3.5 CLIN0007: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.1 [†]: [†]. 

3.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.2.1 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	58
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†].

 3.5.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.5.3
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.5.3.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.5.3.1.1 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	59
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable:
[†] 
 3.5.3.1.2 [†]: [†] 
 Period of Work: [†] 
 Deliverable: [†]. 

3.5.3.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.1.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.2.1 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	60
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.5.3.2.2 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.2.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.2.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.2.5 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.3 [†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	61
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.5.3.3.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.3.2 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.3.4 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†] 

3.5.3.5 [†]: [†]  

Period of Work: [†]. 

Deliverable: [†]. 
 3.5.4
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.5.4.1 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	62
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†].

 3.5.4.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.4.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.4.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.5.5
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.5.5.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 

3.5.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.5.6
[†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	63
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.5.6.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 
 3.
5.6.2 [†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.5.6.3 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 

3.5.6.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.6
CLIN0008: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.6.1 [†]: [†] 

 

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	64
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.6.1.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.6.1.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.1.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.6.2
[†]:         [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	65
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.6.2.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†] 

3.6.2.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.6.3
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†] 
 3.6.3.1 [†]: [†] 

Period of Work: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	66
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†].

 3.6.3.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.3.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.3.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.6.4
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.6.4.1 [†]: [†] 

 

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	67
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†].
 3.6.4.2 [†]: [†]
 Period of Work: [†]. 

Deliverable: [†] 
 3.6.5
[†]: [†] 
 Period of Work: [†]. 
 Deliverable: [†]. 
 3.6.5.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.5.2 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
 3.6.6
[†]: [†] 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	68
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Period of Work:
[†]. 
 Deliverable: [†]. 
 3.6.6.1 [†]: [†] 
 Period of Work: [†]. 

Deliverable: [†]. 

3.6.6.2 [†]: [†] 

Period of Work: [†] 

Deliverable: [†]. 

3.6.6.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	69
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 3.6.7 [†]: [†]

 Period of Work: [†]. 
 Deliverable: [†]. 
 3.6.7.1 Program Management: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.7.2 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.7.3 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.7.4 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†] 
 3.6.8
[†]: [†] 
 Period of Work: [†]. 

 

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	70
	W9113M-09-R-0008	  	restriction on the title page of this proposal.	  	

					
	AVI BioPharma, Inc.	  		  	
	HFV-MARV	  	Final Change Proposal: Statement of Work	  	
		  	16 September 2011	  	

  
 Deliverable: [†].

 3.6.8.1 [†]: [†] 

Period of Work: [†]. 

Deliverable: [†]. 

3.6.8.2 [†]: [†]. 

Period of Work: [†]. 

Deliverable: [†]. 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

  

					
		  	Use or disclosure of data contained on this sheet is subject to the	  	71
	W9113M-09-R-0008	  	restriction on the title page of this proposal.FIRST AMENDMENT TO LEASE DATED AUGUST 30, 2011

 Exhibit 10.4 
 FIRST AMENDMENT TO LEASE 
 THIS FIRST AMENDMENT TO
LEASE (this “Amendment”) is entered into as of this 30th day of August, 2011, by and between BMR-3450 MONTE VILLA PARKWAY LLC, a Delaware limited liability company (“Landlord”), and AVI BIOPHARMA, INC., an Oregon corporation
(“Tenant”). 
 RECITALS 
 A. WHEREAS, Landlord and Tenant entered into that certain Lease dated as of July 27, 2009, as amended by that certain Acknowledgement of Term Commencement Date and Term Expiration Date dated as of
October 7, 2009 (collectively, and as the same may have been further amended, supplemented or modified from time to time, the “Lease”), whereby Tenant leases certain premises (the “Premises”) from Landlord at
3450 Monte Villa Parkway in Bothell, Washington (the “Building”); 
 B. WHEREAS, Tenant wants to extend the
dates for effectiveness of the Termination Option and the Termination Notice due date; and 
 C. WHEREAS, Landlord and Tenant
desire to modify and amend the Lease only in the respects and on the conditions hereinafter stated. 
 AGREEMENT

 NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows: 
 1. Definitions. For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Lease unless otherwise defined herein. 

2. Amendment to Section 3.2. The first sentence of Section 3.2 of the Lease shall be amended and restated in its
entirety to read as follows: 
 “Tenant shall have the one-time option to terminate this Lease (the “Termination
Option”) effective on March 1, 2013 (the “Permitted Early Termination Date”) (except for those provisions that expressly survive the expiration or earlier termination of this Lease) upon delivery of written notice to
Landlord no later than March 1, 2012 (the “Termination Notice”); provided that Tenant pay to Landlord at the time Tenant delivers to Landlord the Termination Notice a termination fee equal to Two Hundred Ten Thousand
Five Hundred Fifty and 12/100 Dollars ($210,550.12), which Landlord and Tenant agree equals the sum of (a) any unamortized TI Allowance, (b) any unamortized broker fees or commissions and (c) one month of Base Rent at the rate in
effect at the time of Tenant’s exercise of the Termination Option (collectively, the “Termination Fee”).” 

 3. Broker. Tenant represents and warrants that it has not dealt with any broker or
agent in the negotiation for or the obtaining of this Amendment other than EDG Commercial Real Estate and agrees to indemnify, defend and hold Landlord harmless from any and all cost or liability for compensation claimed by any other broker or agent
employed or engaged by it. 
 4. No Default. Tenant represents, warrants and covenants that, to Tenant’s actual
knowledge, without inquiry, Landlord and Tenant are not in default of any of their respective obligations under the Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either
Landlord or Tenant thereunder. 
 5. Effect of Amendment. Except as modified by this Amendment, the Lease and all the
covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. The covenants, agreements, terms, provisions and conditions contained in this Amendment shall bind and inure
to the benefit of the parties hereto and their respective successors and, except as otherwise provided in the Lease, their respective assigns. In the event of any conflict between the terms contained in this Amendment and the Lease, the terms herein
contained shall supersede and control the obligations and liabilities of the parties. From and after the date hereof, the term “Lease” as used in the Lease shall mean the Lease, as modified by this Amendment. 

6. Mortgagee Consent. Landlord represents that there is currently no mortgagee with respect to the Property. 

7. Miscellaneous. This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of
the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference.
Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and
Tenant. 
 8. Counterparts. This Amendment may be executed in one or more counterparts, each of which, when taken
together, shall constitute one and the same document. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 2 

 IN WITNESS WHEREOF, Landlord and Tenant have hereunto set their hands as of the date and
year first above written, and acknowledge that they possess the requisite authority to enter into this transaction and to execute this Amendment. 
 LANDLORD: 
  

			
	BMR-3450 MONTE VILLA PARKWAY LLC,
	a Delaware limited liability company
		
	By:	 	 /s/ John Bonanno

	Name:	 	 John Bonanno

	Title:	 	 Sr. Vice President, Leasing & Development

 TENANT: 
  

			
	AVI BIOPHARMA, INC.,
	an Oregon corporation
		
	By:	 	 /s/ Christopher Garabedian

	Name:	 	 Christopher Garabedian

	Title:	 	 President and Chief Executive Officer

 STATE OF WASHINGTON ) 
                                   
                : ss. 
 COUNTY OF SNOHOMISH ) 

I certify that I know or have satisfactory evidence that Christopher Garabedian is the person who appeared before me, and he acknowledged
that he signed this instrument, on oath stated that he was authorized to execute the instrument and acknowledged it as the Chief Executive Officer of AVI BioPharma, Inc., a corporation, to be the free and voluntary act of such corporation for the
uses and purposes mentioned in the instrument. 
 Dated this 31 day of August, 2011. 

 

	
	 /s/ Wendy M. Cort

	[Signature of Notary]
	
	 Wendy M. Cort

	[Print Name of Notary]
	
	Notary Public in and for the State of Washington, residing at 3450 Monte Villa Parkway, Bothell.
	My commission expires: 10/16/13.

  

							
	  
 STATE OF CALIFORNIA

 
 COUNTY OF SAN DIEGO

 
	 	}	 	  	  	ss.

 On August 30, 2011, before me, Nicole L. Smith, a Notary Public in and for said County and State,
personally appeared John Bonanno, 

                         
                                         
                                         
                                         
                                         
                                         
                          , 
  

					
	 who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and
acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

 
 I certify under PENALTY OF PERJURY under the laws of the State of California that
the foregoing paragraph is true and correct.
	 		  	FOR NOTARY SEAL OR STAMP

  

			
	WITNESS my hand and official seal.
	Signature	 	 /s/ Nicole L. Smith

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]